# Analysis: SYK_2024_Q4.txt

*Model: gpt-4o*

---

**Quarter & Company Context**

- **Company Name:** Stryker Corporation
- **Ticker:** SYK
- **Fiscal Quarter/Year:** Q4 2024
- **Key Macro or Industry Context:** The company is operating in a robust MedTech market with strong procedural volumes and capital product demand. The acquisition of Inari Medical is highlighted as a strategic move into the peripheral vascular market, which is a logical adjacency to Stryker's neurovascular division.

**Headline Financial Results**

- **Revenue:** Organic sales growth exceeded 10% for both Q4 and the full year.
- **EPS:** Adjusted EPS of $4.01 for Q4 and $12.19 for the full year, representing 16% and 15% growth, respectively.
- **Margins:** Improved operating margins with a 200 basis point increase in Q4 and 110 basis points for the full year.
- **Guidance:** For 2025, organic sales growth is expected to be 8-9%, with an adjusted EPS of $13.45 to $13.70, excluding the impact of the Inari acquisition.

**Management Commentary**

- **Strategic Initiatives:** Acquisition of Inari Medical to expand into the mechanical thrombectomy market for venous thromboembolism (VTE), representing a significant growth opportunity.
- **Product Launches:** Strong momentum in Mako installations, with new launches in Mako Spine and Mako Shoulder.
- **Risks/Challenges:** Sale of the spinal implants business due to underperformance, focusing resources on high-growth areas.

**Q&A Highlights**

- **Main Themes:** Analysts focused on the spine sale, Inari acquisition, and margin expansion strategies.
- **Management Tone:** Confident about growth prospects and integration of acquisitions. Emphasis on strategic focus and operational efficiencies.

**Market/Investor Sentiment Signals**

- **Forward-looking Commentary:** Positive outlook on procedural volumes, capital product demand, and continued innovation.
- **Surprises vs. Expectations:** Strong organic growth and margin expansion despite multiple acquisitions and divestitures.

**Takeaways**

- Stryker delivered strong financial performance with double-digit organic growth and margin expansion.
- The acquisition of Inari Medical positions Stryker in a high-growth peripheral vascular market.
- Divestiture of the spinal implants business aligns with strategic focus on high-growth areas.
- Continued investment in R&D and product innovation supports long-term growth prospects.
- Management remains confident in achieving 2025 guidance and sustaining growth momentum.

**Other Notable Information**

- **Leadership Changes:** CFO Glenn Bainline announced his retirement, with Preston Wells succeeding him.
- **M&A Activity:** Seven acquisitions completed in 2024, with a focus on strategic adjacencies and tuck-in deals.
- **Regulatory Considerations:** Due diligence on Inari acquisition included evaluation of a DOJ investigation, with management expressing confidence in the transaction.